Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

1,180

Participants

Timeline

Start Date

December 30, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Ischemic StrokeIntracranial AtherosclerosisStenosis

Interventions

DRUG

Rivaroxaban

Rivaroxaban (2.5mg orally twice a day for 90 days)

DRUG

Clopidogrel

Clopidogrel (300mg loading dose, then 75mg once daily for 90 days)

DRUG

Aspirin

Aspirin (100mg once a day for 1 year)

OTHER

Risk Factor Management in both arms

Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed

All Listed Sponsors

collaborator

National Natural Science Foundation of China

OTHER_GOV

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT05700266 - Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis | Biotech Hunter | Biotech Hunter